Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis
Authors:
- Sunidhi JaiswalSJSunidhi Jaiswal
- Siamak AmirfakhriSASiamak Amirfakhri
- Javier BravoJBJavier Bravo
- Keita KobayashiKKKeita Kobayashi
- Abhijit AithalAAAbhijit Aithal
- Sumbal TalibSTSumbal Talib
- Kavita MallyaKMKavita Mallya
- Maneesh JainMJManeesh Jain
- Aaron M. MohsAMAaron M. Mohs
- Robert M. HoffmanRHRobert M. Hoffman
- Surinder K. BatraSBSurinder K. Batra
- Michael BouvetMichael Bouvet
Open Access
Abstract
Background/Objectives: Pancreatic cancer is the fourth leading cause of deaths related to cancer. It is a highly aggressive malignancy and often metastasizes quickly to other parts of the body and organs. The most effective cure is surgical resection, which also is limited by tumor identification and clear tumor margin visualization. Previously, we used MUC4 antibodies labeled with IRDye800CW (anti-MUC4-IR800) to target primary human pancreatic cancer in orthotopic cell line mouse models. Methods: In the present study, we established a pancreatic cancer liver metastasis mouse model by implanting a tumor fragment in the liver and a peritoneal carcinomatosis mouse model by injecting pancreatic cancer cells interperitoneally. Once the tumors were established, anti-MUC4-IR800 was administered to the mice by tail vein injection. Laparotomy was performed and tumors were imaged under white-light and near-infrared (NIR) fluorescence with the Pearl Small Animal Imaging System. Results: NIR imaging after 72 h shows the bright targeting of pancreatic cancer metastasis in both mouse models with high tumor-to-background ratios. Conclusions: Anti-MUC4-IR800 was able to successfully target and brightly label metastatic pancreatic cancer as small as 1 mm. Future clinical applications of the results of the present study are discussed.Keywords
Funding Information
- National Institutes of Health (R01 CA256973, R01 CA259080)
- VA Merit Review (I01 BX003856)
- National Institute of Health Training Grant (T32CA121938)
This publication has 34 references indexed in Scilit:
- Panitumumab‐IRDye800 Improves Laryngeal Tumor Mapping During Transoral Laser MicrosurgeryThe Laryngoscope, 2023
- The Evolution of Fluorescence-Guided SurgeryMolecular Imaging and Biology, 2022
- Molecular mediators of peritoneal metastasis in pancreatic cancerCancer and Metastasis Reviews, 2020
- The enhancement of glycolysis regulates pancreatic cancer metastasisCellular and Molecular Life Sciences, 2019
- First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800Journal of Neuro-Oncology, 2018
- Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancerBritish Journal of Surgery, 2017
- SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgerySurgical Oncology, 2017
- Palliative Surgical Management of Patients with Unresectable Pancreatic Adenocarcinoma: Trends and Lessons Learned from a Large, Single Institution ExperienceJournal of Gastrointestinal Surgery, 2011
- Patterns of Recurrence After Curative Resection of Pancreatic Cancer, Based on Autopsy FindingsJournal of Gastrointestinal Surgery, 2006
- Expression of MUC1, MUC2, MUC3 and MUC4 mucin mrnas in human pancreatic and intestinal tumor cell linesInternational Journal of Cancer, 1994